Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Beam Therapeutics Inc (BEAM)

Beam Therapeutics Inc (BEAM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Image by Sorapop Udomsri via Shutterstock
2 Stocks to Buy Now to Profit from the Rise of Robotics Barchart - Tue Nov 4, 6:30AM CST

Investors betting on the future of automation in high-tech manufacturing would do well to keep these two stocks on their radar.

BEAM : 21.55 (-0.46%)
LCID : 17.32 (+0.81%)
ROK : 390.50 (-0.19%)
BA : 195.18 (+0.19%)
Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates GlobeNewswire - Tue Nov 4, 6:00AM CST

Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin Deficiency Ongoing; Updated Data and Clinical Development Update Expected in Early 2026...

BEAM : 21.55 (-0.46%)
Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting GlobeNewswire - Mon Nov 3, 8:00AM CST

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

BEAM : 21.55 (-0.46%)
H.C. Wainwright Reaffirms Their Buy Rating on Beam Therapeutics (BEAM) Tipranks - Sat Oct 11, 5:54AM CDT

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Beam Therapeutics today and set a price target of $80.00. The company’s shares closed yesterday at $27.87.Elevate Your Investing Strategy:...

BEAM : 21.55 (-0.46%)
Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences GlobeNewswire - Mon Aug 25, 6:00AM CDT

CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

BEAM : 21.55 (-0.46%)
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease GlobeNewswire - Thu Aug 14, 6:00AM CDT

CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

BEAM : 21.55 (-0.46%)
BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark
BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark Zacks Investment Research - Wed Aug 6, 11:56AM CDT

Beam Therapeutics BEAM incurred a loss of $1.00 per share in the second quarter of 2025, which was narrower than the Zacks Consensus Estimate of a loss of $1.04. The company had reported a loss of $1.11...

BEAM : 21.55 (-0.46%)
IMCR : 35.30 (+0.86%)
ARVN : 11.44 (+2.23%)
CRMD : 10.97 (-0.99%)
Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) GlobeNewswire - Tue Aug 5, 6:00AM CDT

With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Continues to Demonstrate Durable Correction of the Disease-causing Mutation, Restoration of AAT Physiology, and a Well Tolerated Safety Profile ...

BEAM : 21.55 (-0.46%)
Innovation ETF (ARKK) Hits New 52-Week High
Innovation ETF (ARKK) Hits New 52-Week High Zacks Investment Research - Wed Jul 9, 11:00AM CDT

For investors seeking momentum, ARK Innovation ETF ARKK is probably on the radar. The fund just hit a 52-week high and is up about 92.4% from its 52-week low price of $36.85/share. But are more gains...

BEAM : 21.55 (-0.46%)
ROKU : 105.71 (+0.68%)
CRSP : 53.80 (-1.43%)
MASS : 6.04 (-5.48%)
ARKK : 82.05 (-0.95%)
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential Motley Fool - Sat Jun 28, 8:10AM CDT

BEAM : 21.55 (-0.46%)
INSP : 87.65 (+1.84%)
LFMD : 5.06 (-1.36%)
KRYS : 200.34 (+0.41%)
OPCH : 28.20 (+0.07%)
VEEV : 296.82 (+0.36%)
TMDX : 122.27 (-0.10%)
PODD : 324.02 (+1.15%)
CERT : 8.44 (-2.09%)
TEM : 71.78 (+0.59%)

Barchart Exclusives

Is This Beaten-Down Cathie Wood Stock Still a Buy? Barchart - Tue Nov 11, 6:30AM CST
Intellia’s shares plunged 23% after its Q3 results showed a pipeline setback. Nonetheless, Cathie Wood’s stake in the company is expanding. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot